Lincoln Pharmaceuticals peers

·Pharma & HealthChart ›

Companies like Lincoln Pharmaceuticalslatest year

Lincoln PharmaceuticalsLINCOLN · FY26 · this company
Market cap₹1,118
P/E12.72×
Sales growth+17.1%
ROE12.3%
Sigachi IndustriesSIGACHI · FY26
Open ›
Market cap₹1,014
P/E—
Sales growth−5.4%
ROE−14.6%
Themis MedicareTHEMISMED · FY26
Open ›
Market cap₹907
P/E820.33×
Sales growth−10.9%
ROE0.3%
Bajaj HealthcareBAJAJHCARE · FY26
Open ›
Market cap₹1,059
P/E63.14×
Sales growth+18.9%
ROE3.2%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LINCOLN₹558.10

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,118 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LINCOLN
FY26
SIGACHI
FY26
THEMISMED
FY26
BAJAJHCARE
FY26
Peer
Average
Valuation — at last close
P/E◆ 12.72×—820.33×63.14×441.74× -97%
P/B◆ 1.48×1.94×2.27×1.99×2.07× -29%
EV/EBITDA◆ 9.02×21.04×2537.06×11.96×856.69× -99%
Market Cap₹1,118 Cr₹1,014 Cr₹907 Cr₹1,059 Cr₹993 Cr +13%
Growth
Revenue CAGR 3Y9.56%◆ 16.52%-1.15%-3.18%4.06% +135%
Revenue CAGR 5Y——8.21%—8.21%
Net Income CAGR 3Y◆ 6.43%—-72.81%-28.44%-50.63% +113%
Revenue YoY (latest Q)17.13%-5.44%-10.88%◆ 18.92%0.87% +1877%
Net Income YoY (latest Q)2.21%108.07%◆ 273.08%26.87%136.01% -98%
Profitability
EBITDA Margin14.56%11.25%0.11%◆ 17.15%9.50% +53%
Net Income Margin◆ 13.10%-17.33%0.33%2.58%-4.81% +373%
Return on Common Equity◆ 12.30%-14.57%0.29%3.16%-3.71% +432%
Return on Capital Employed11.32%5.87%-2.30%◆ 13.27%5.61% +102%
Return on Assets◆ 10.42%-9.81%0.19%1.80%-2.61% +500%
Credit & Quality
Total Debt/Equity◆ 0.01×0.26×0.25×0.44×0.32× -97%
Interest Coverage◆ 82.12×2.60×-0.93×3.48×1.72× +4684%
Scale — latest FY
Revenue / Total Income₹671 Cr₹478 Cr₹342 Cr₹611 Cr₹477 Cr +41%
Net Income₹87.9 Cr−₹82.8 Cr₹1.1 Cr₹15.8 Cr−₹22 Cr +500%
Total Assets₹890 Cr₹841 Cr₹598 Cr₹923 Cr₹787 Cr +13%
EPS₹43.88₹-2.14₹0.12₹4.98₹0.99 +4347%
Book Value per Share₹378.25₹13.65₹43.28₹158.34₹71.76 +427%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.